Metabolomic evaluation of neutrophilic airway inflammation in cystic fibrosis

Chest

Volumn 148, Issue 2, 2015, Pages 507-515

  Esther, Charles R ^a   Coakley, Raymond D ^b   Henderson, Ashley G ^b   Zhou, Yi Hui ^c   Wright, Fred A ^c   Boucher, Richard C ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE; POLYAMINE; PROTEIN; PURINE; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HUMAN; LUNG FUNCTION; MALE; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; NEUTROPHIL COUNT; NEUTROPHILIC AIRWAY INFLAMMATION; POLYAMINE METABOLISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PURINE METABOLISM; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; VALIDATION PROCESS; BRONCHOALVEOLAR LAVAGE FLUID; CASE CONTROL STUDY; CHEMISTRY; IMMUNOLOGY; INFANT; INFLAMMATION; LUNG FUNCTION TEST; METABOLISM; METABOLOME; MIDDLE AGED; NEUTROPHIL; PATHOPHYSIOLOGY; PRESCHOOL CHILD; SMOKING; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INFANT; INFLAMMATION; MALE; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MIDDLE AGED; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SMOKING; YOUNG ADULT;

EID: 84939219512     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-1800     Document Type: Article

References (40)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005; 352 (19): 1992-2001.
2. Alton EW, Davies JC, Geddes DM. Biomarkers for cystic fibrosis: are we progressing? Am J Respir Crit Care Med. 2007; 175 (8): 750-751.
3. Mayer-Hamblett N, Aitken ML, Accurso FJ, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med. 2007; 175 (8): 822-828.
4. Esther CR Jr. Alexis NE, Clas ML, et al. Extracellular purines are biomarkers of neutrophilic airway inflammation. E ur Respir J. 2008; 31 (5): 949-956.
5. Wolak JE, Esther CR Jr. O'Connell TM. Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients. Biomarkers. 2009; 14 (1): 55-60.
6. Yang J, Eiserich JP, Cross CE, Morrissey BM, Hammock BD. Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. F ree Radic Biol Med. 2012; 53 (1): 160-171.
7. de Laurentiis G, Paris D, Melck D, et al. Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy. Eur Respir J. 2008; 32 (5): 1175-1183.
8. Sofia M, Maniscalco M, de Laurentiis G, Paris D, Melck D, Motta A. Exploring airway diseases by NMR-based metabonomics: a review of application to exhaled breath condensate. J Biomed Biotechnol. 2011;2011:403260.
9. Sagel SD. Noninvasive biomarkers of airway inflammation in cystic fibrosis. Curr Opin Pulm Med. 2003; 9 (6): 516-521.
10. Sumner SJ, Burgess JP, Snyder RW, Popp JA, Fennell TR. Metabolomics of urine for the assessment of microvesicular lipid accumulation in the liver following isoniazid exposure. Metabolomics. 2010; 6 (2): 238-249.
11. RansohoffDF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol. 2007; 60 (12): 1205-1219.
12. Qiu Y, Cai G, Su M, et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009; 8 (10): 4844-4850.
13. Esther CR Jr. Jasin HM, Collins LB, Swenberg JA, Boysen G. A mass spectrometric method to simultaneously measure a biomarker and dilution marker in exhaled breath condensate . Rapid Commun Mass Spectrom. 2008; 22 (5): 701-705.
14. Esther CR Jr. Lazaar AL, Bordonali E, Qaqish B, Boucher RC. Elevated airway purines in COPD. Chest. 2011; 140 (4): 954-960.
15. Zhou YH, Barry WT, Wright FA. Empirical pathway analysis, without permutation . B iostatistics. 2013; 14 (3): 573-585.
16. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantifi cation of the small-molecule complement of biological systems. Anal Chem. 2009; 81 (16): 6656-6667.
17. Bajad SU, Lu W, Kimball EH, Yuan J, Peterson C, Rabinowitz JD. Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry . J Chromatogr A. 2006; 1125 (1): 76-88.
18. Kamatani N, Carson DA. Dependence of adenine production upon polyamine synthesis in cultured human lymphoblasts. Biochim Biophys Acta. 1981; 675 (3-4): 344-350.
19. Birrer P, McElvaney NG, Rüdeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med. 1994; 150(1): 207-213.
20. Esther CR Jr. Olsen BM, Lin FC, Fine J, Boucher RC. Exhaled breath condensate adenosine tracks lung function changes in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2013; 304 (7): L504-L509.
21. Grasemann H, Shehnaz D, Enomoto M, Leadley M, Belik J, Ratjen F. L-ornithine derived polyamines in cystic fibrosis airways. PLoS ONE. 2012; 7 (10): e46618.
22. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol. 2008; 180 (8): 5662-5669.
23. Haslam PL, Baughman RP. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J. 1999; 14 (2): 245-248.
24. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med. 1999; 160 (1): 186-191.
25. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation . N Engl J Med. 2012; 367 (24): 2322-2333.
26. Esther CR Jr. Peden DB, Alexis NE, Hernandez ML. Airway purinergic responses in healthy, atopic nonasthmatic, and atopic asthmatic subjects exposed to ozone. Inhal Toxicol. 2011; 23 (6): 324-330.
27. Boda D. Role of hyperuricaemia in critically ill patients especially newborns . Acta Paediatr Acad Sci Hung. 1984; 25 (1-2): 23-32.
28. Quinlan GJ, Lamb NJ, Tilley R, Evans TW, Gutteridge JM. Plasma hypoxanthine levels in ARDS: implications for oxidative stress, morbidity, and mortality. Am J Respir Crit Care Med. 1997; 155 (2): 479-484.
29. Gandhi V, Balakrishnan K. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Semin Oncol. 2007; 34 (6 s uppl 5): S8-S12.
30. Griese M, Kappler M, Gaggar A, Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J. 2008; 32 (3): 783-795.
31. Thomas SR, Ray A, Hodson ME, Pitt TL. Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax. 2000; 55 (9): 795-797.
32. Barth AL, Pitt TL. The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic P seudomonas aeruginosa. J Med Microbiol. 1996; 45 (2): 110-119.
33. Chen H, Macleod C, Deng B, et al. CAT-2 amplifies the agonist-evoked force of airway smooth muscle by enhancing spermine-mediated phosphatidylinositol-(4)-phosphate-5-kinase-gamma activity. Am J Physiol Lung Cell Mol Physiol. 2007; 293 (4): L883-L891.
34. Chen EY, Wang YC, Chen CS, Chin WC. Functionalized positive nanoparticles reduce mucin swelling and dispersion. PLoS ONE. 2010; 5 (11): e15434.
35. Wright FA, Strug LJ, Doshi VK, et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. N at Genet. 2011; 43 (6): 539-546.
36. Koch-Nolte F, Fischer S, Haag F, Ziegler M. Compartmentation of NAD 1-dependent signalling. FEBS Lett. 2011; 585 (11): 1651-1656.
37. Paone G, Stevens LA, Levine RL, et al. ADP-ribosyltransferase-specific modifi-cation of human neutrophil peptide-1. J Biol Chem. 2006; 281 (25): 17054-17060.
38. Esther CR Jr. Boysen G, Olsen BM, et al. Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2009; 296 (6): L987-L993.
39. Alexis NE, Hu SC, Zeman K, Alter T, Bennett WD. Induced sputum derives from the central airways: confirmation using a radiolabeled aerosol bolus delivery technique. Am J Respir Crit Care Med. 2001; 164 (10 pt 1): 1964-1970.
40. Fabian P, Brain J, Houseman EA, Gern J, Milton DK. Origin of exhaled breath particles from healthy and human rhinovirus-infected subjects. J Aerosol Med Pulm Drug Deliv. 2011; 24 (3): 137-147.